Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

STANFORD UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1885-11-11

Employees: 10K

Market Cap: -

Website: http://www.stanford.edu

Clinical Trials

A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis

Phase 1

Not yet recruiting

Conditions: Primary Progressive Multiple Sclerosis
Multiple Sclerosis
Multiple Sclerosis, Primary Progressive
Multiple Sclerosis, Secondary Progressive

Interventions: Biological: Orca-Q
Drug: myeloablative regimen

First Posted Date: 2025-03-28

Last Posted Date: 2025-03-28

Lead Sponsor: Stanford University

Target Recruit Count: 10

Registration Number: NCT06900192

Targeted Realtime Assessment of Chronic Pain in Youth

Recruiting

Conditions: Chronic Pain
Musculoskeletal Pain

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-25

Lead Sponsor: Stanford University

Target Recruit Count: 500

Registration Number: NCT06867757

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States

Managing Transient Neurologic Episodes in Surgery for Moyamoya Disease

Recruiting

Conditions: Moya Moya Disease

First Posted Date: 2025-03-17

Last Posted Date: 2025-05-28

Lead Sponsor: Stanford University

Target Recruit Count: 88

Registration Number: NCT06880341

Locations: 🇺🇸
Stanford University Hospital, Palo Alto, California, United States

LLM-Generated Coaching Prompts

Not Applicable

Not yet recruiting

Conditions: Exercise

First Posted Date: 2025-03-17

Last Posted Date: 2025-03-20

Lead Sponsor: Stanford University

Target Recruit Count: 50

Registration Number: NCT06880315

A Trial of Baricitinib in Patients With Cardiac Sarcoidosis

Phase 2

Not yet recruiting

Conditions: Cardiac Sarcoidosis

Interventions: Drug: Baricitinib (LY3009104) 4 mg

First Posted Date: 2025-03-10

Last Posted Date: 2025-06-11

Lead Sponsor: Stanford University

Target Recruit Count: 10

Registration Number: NCT06868381

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States

Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)

Phase 2

Recruiting

Conditions: Glioma
GBM

First Posted Date: 2025-03-04

Last Posted Date: 2025-03-04

Lead Sponsor: Stanford University

Target Recruit Count: 10

Registration Number: NCT06855628

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States

Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes

Not Applicable

Not yet recruiting

Conditions: Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes

First Posted Date: 2025-02-20

Last Posted Date: 2025-02-20

Lead Sponsor: Stanford University

Target Recruit Count: 30

Registration Number: NCT06836479

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Feasibility Usability & Acceptability Study: Symptom Reporting by Children Adolescents & Young Adults w/Cancer

Not Applicable

Recruiting

Conditions: Adolescent Behavior
Pediatric Cancer
Oncology

First Posted Date: 2025-02-13

Last Posted Date: 2025-02-13

Lead Sponsor: Stanford University

Target Recruit Count: 70

Registration Number: NCT06824441

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States

Sleep TMS for Depression

Not Applicable

Not yet recruiting

Conditions: Major Depression
Sleep

First Posted Date: 2025-02-13

Last Posted Date: 2025-05-06

Lead Sponsor: Stanford University

Target Recruit Count: 15

Registration Number: NCT06824415

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

Phase 2

Not yet recruiting

Conditions: Hypophosphatemia
Kidney Transplantation

Interventions: Drug: Dipyridamole 75 MG

First Posted Date: 2025-02-13

Last Posted Date: 2025-02-13

Lead Sponsor: Stanford University

Target Recruit Count: 90

Registration Number: NCT06824454

Locations: 🇺🇸
Stanford University, Stanford, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy